Skip to Content
  • Current Oncology is published by MDPI from Volume 28 Issue 1 (2021). Previous articles were published by another publisher in Open Access under a CC-BY (or CC-BY-NC-ND) licence, and they are hosted by MDPI on mdpi.com as a courtesy and upon agreement with Multimed Inc..

Current Oncology, Volume 23, Issue 5

2016 October - 25 articles

  • Issues are regarded as officially published after their release is announced to the table of contents alert mailing list .
  • You may sign up for email alerts to receive table of contents of newly released issues.
  • PDF is the official format for papers published in both, html and pdf forms. To view the papers in pdf format, click on the "PDF Full-text" link, and use the free Adobe Reader to open them.

Articles (25)

  • Article
  • Open Access
8 Citations
1,283 Views
6 Pages

Association between Basal-Like Phenotype and BRCA1/2 Germline Mutations in Korean Breast Cancer Patients

  • J. Jung,
  • E. Kang,
  • J.M. Gwak,
  • A.N. Seo,
  • S.Y. Park,
  • A.S. Lee,
  • H. Baek,
  • S. Chae,
  • E.K. Kim and
  • S.W. Kim

1 October 2016

Introduction: BRCA mutation testing allows index patients and their families to be provided with appropriate cancer risk-reduction strategies. Because of the low prevalence of BRCA mutations in unselected breast cancer patients and the high cost of g...

  • Article
  • Open Access
13 Citations
1,318 Views
10 Pages

A Time-and-Motion Approach to Micro-Costing of High-Throughput Genomic Assays

  • S. Costa,
  • D.A. Regier,
  • B. Meissner,
  • I. Cromwell,
  • S. Ben-Neriah,
  • E. Chavez,
  • S. Hung,
  • C. Steidl,
  • D.W. Scott and
  • J.M. Connors
  • + 2 authors

1 October 2016

Background: Genomic technologies are increasingly used to guide clinical decision-making in cancer control. Economic evidence about the cost-effectiveness of genomic technologies is limited, in part because of a lack of published comprehensive cost e...

  • Article
  • Open Access
44 Citations
1,369 Views
8 Pages

1 October 2016

Background: Breast-conserving surgery (BCS) is the preferred surgical approach for most patients with early-stage breast cancer. Frequently, concerns arise about the pathologic margin status, resulting in an average reoperation rate of 23% in Canada....

  • Article
  • Open Access
9 Citations
746 Views
7 Pages

1 October 2016

The pan-Canadian Oncology Drug Review (PCODR) is responsible for making coverage recommendations to provincial and territorial drug plans about cancer drugs. Within the pcodr process, small groups of experts (including public representatives) conside...

  • Article
  • Open Access
6 Citations
1,067 Views
5 Pages

Patterns of Practice with Third-Line Anti-EGFR Antibody for Metastatic Colorectal Cancer

  • M.Y. Ho,
  • D.J. Renouf,
  • W.Y. Cheung,
  • H.J. Lim,
  • C.H. Speers,
  • C. Zhou and
  • H.F. Kennecke

1 October 2016

Background: Therapy with anti-epidermal growth factor receptor (EGFR) monoclonal antibody improves outcomes for patients with metastatic colorectal cancer (MCRC) in the first-, second-, and third-line trial settings. In British Columbia, the use of E...

  • Article
  • Open Access
13 Citations
979 Views
9 Pages

Predictors of Adjuvant Treatment for Pancreatic Adenocarcinoma at the Population Level

  • D.J. Kagedan,
  • M.E. Dixon,
  • R.S. Raju,
  • Q. Li,
  • M. Elmi,
  • E. Shin,
  • N. Liu,
  • A. El-Sedfy,
  • L. Paszat and
  • N.G. Coburn
  • + 3 authors

1 October 2016

Background: In the present study, we aimed to describe, at the population level, patterns of adjuvant treatment use after curative-intent resection for pancreatic adenocarcinoma (PCC) and to identify independent predictors of adjuvant treatment use....

  • Guidelines
  • Open Access
10 Citations
1,009 Views
8 Pages

1 October 2016

Background: A need for follow-up recommendations for survivors of fallopian tube, primary peritoneal, or epithelial ovarian cancer after completion of primary treatment was identified by Cancer Care Ontario’s Program in Evidence-Based Care. Methods:...

  • Article
  • Open Access
14 Citations
1,012 Views
5 Pages

Use of Low-Value Radiotherapy Practices in Canada: An Analysis of Provincial Cancer Registry Data

  • K. Tran,
  • R. Rahal,
  • M. Brundage,
  • S. Fung,
  • C. Louzado,
  • M. Milosevic,
  • J. Xu,
  • H. Bryant and
  • Technical Working Group

1 October 2016

Background: As part of Choosing Wisely Canada (a national campaign to encourage patient–provider conversations about unnecessary medical tests, treatments, and procedures), a list of ten oncology practices that could be low-value in some instances wa...

  • Article
  • Open Access
2 Citations
975 Views
5 Pages

1 October 2016

Introduction: After stereotactic radiosurgery (SRS) for brain metastases, patients are routinely monitored with magnetic resonance imaging (MRI). The high rate of new brain metastases after SRS treatment alone might not be as concerning with modern M...

  • Article
  • Open Access
14 Citations
1,248 Views
4 Pages

Serum Carcinoembryonic Antigen as a Tumour Marker in Patients with Endometrial Cancer

  • Y. Hashiguchi,
  • M. Kasai,
  • T. Fukuda,
  • T. Ichimura,
  • T. Yasui and
  • T. Sumi

1 October 2016

Background: No potential tumour markers have been validated for prognosis in endometrial cancer. However, carcinoembryonic antigen (CEA) is one of the most widely used tumour markers in various types of cancer. Although CEA expression in endometrial...

  • Article
  • Open Access
11 Citations
1,210 Views
11 Pages

Long-Term Health Care Costs for Prostate Cancer Patients on Androgen Deprivation Therapy

  • M.D. Krahn,
  • K.E. Bremner,
  • J. Luo,
  • G. Tomlinson and
  • S.M.H. Alibhai

1 October 2016

Background: Comparing relative costs for androgen deprivation therapy (ADT) protocols in prostate cancer (PCa) requires an examination of all health care resources, not only those specific to PCa. The objective of the present study was to use adminis...

  • Article
  • Open Access
22 Citations
1,453 Views
7 Pages

1 October 2016

Background: The primary objective of the present study was to examine the drug approval process and the time to approval (TTA) for cancer drugs by 3 major international regulatory bodies—Health Canada, the U.S. Food and Drug Administration (FDA), and...

  • Article
  • Open Access
10 Citations
1,848 Views
7 Pages

The Cost-Effectiveness of Bevacizumab for the Treatment of Advanced Ovarian Cancer in Canada

  • M. Duong,
  • E. Wright,
  • L. Yin,
  • I. Martin-Nunez,
  • P. Ghatage and
  • M. Fung-Kee-Fung

1 October 2016

Background: The overall survival (OS) analysis of the icon7 trial demonstrated that frontline ovarian cancer patients with a high risk of progression (stage III suboptimally debulked, and stage III or IV with unresectable disease) benefited from the...

  • Article
  • Open Access
10 Citations
1,338 Views
4 Pages

Progression Pattern and Adverse Events with Bevacizumab in Glioblastoma

  • A. Mamo,
  • A. Baig,
  • M. Azam,
  • Y.S. Rho,
  • S. Sahebjam,
  • T. Muanza,
  • S. Owen,
  • K. Petrecca,
  • M.C. Guiot and
  • P. Kavan
  • + 2 authors

1 October 2016

Background: The use of bevacizumab in the management of glioblastoma multiforme (gbm) remains controversial. In Canada, bevacizumab is approved for the treatment of recurrent gbm. We describe a pattern of progression across treatment lines in gbm. Me...

  • Article
  • Open Access
13 Citations
1,149 Views
9 Pages

Combined Sorafenib and Yttrium-90 Radioembolization for the Treatment of Advanced Hepatocellular Carcinoma

  • A. Salman,
  • E. Simoneau,
  • M. Hassanain,
  • P. Chaudhury,
  • L.M. Boucher,
  • D. Valenti,
  • T. Cabrera,
  • C. Nudo and
  • P. Metrakos

1 October 2016

Background and Aims: In this pilot study, we assessed the safety and tolerability of combining sorafenib with 90Y radioembolization for the treatment of unresectable hepatocellular carcinoma (HCC). Methods: The study, conducted prospectively during 2...

  • Article
  • Open Access
39 Citations
1,233 Views
7 Pages

Bioelectrical Impedance Phase Angle as a Prognostic Indicator of Survival in Head-and-Neck Cancer

  • M.S. Władysiuk,
  • R. Mlak,
  • K. Morshed,
  • W. Surtel,
  • A. Brzozowska and
  • T. Małecka-Massalska

1 October 2016

Background: Phase angle could be an alternative to subjective global assessment for the assessment of nutrition status in patients with head-and-neck cancer. Methods: We prospectively evaluated a cohort of 75 stage IIIB and IV head-and-neck patients...

  • Article
  • Open Access
7 Citations
943 Views
11 Pages

1 October 2016

Aim: In the present study, we synthesized the published literature about the psychosocial aspects of colorectal cancer (crc) survivorship to support an update of the evidentiary base of the survivorship care plans (scps) created in our jurisdiction....

  • Article
  • Open Access
7 Citations
892 Views
15 Pages

Follow-Up Care for Survivors of Lymphoma Who Have Received Curative-Intent Treatment

  • J. Sussman,
  • N.P. Varela,
  • M. Cheung,
  • L. Hicks,
  • D. Kraftcheck,
  • J. Mandel,
  • G. Fraser,
  • L. Jimenez-Juan,
  • A. Boudreau and
  • R. McQuillan
  • + 1 author

1 October 2016

Objective: This evidence summary set out to assess the available evidence about the follow-up of asymptomatic survivors of lymphoma who have received curative-intent treatment. Methods: The MEDLINE and EMBASE databases and the Cochrane Database of Sy...

  • Article
  • Open Access
4 Citations
748 Views
3 Pages

1 October 2016

Case Description: A 60-year-old man developed painless neutropenic enterocolitis after induction chemotherapy for newly diagnosed acute myelogenous leukemia. The patient had recurrent fever while neutropenic, without experiencing abdominal pain or te...

  • Review
  • Open Access
11 Citations
757 Views
4 Pages

1 October 2016

We present here a very rare clinical case of a 38-year-old man with Kaposiform hemangioendothelioma (KHE) of the tongue who presented to our institution with a growth under the left side of the tongue with no pain or discomfort. There were no enlarge...

XFacebookLinkedIn
Curr. Oncol. - ISSN 1718-7729